Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Lyra Therapeutics Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 54 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.96 |
|---|---|
| 52-week range | $3.30 - $16.50 |
| 50-day moving average | $4.98 |
| 200-day moving average | $7.34 |
| Wall St. target price | $22.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.85 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.96 from 2022-01-25
| 1 week (2022-01-18) | -2.22% |
|---|---|
| 1 month (2021-12-27) | -14.66% |
| 3 months (2021-10-27) | -46.12% |
| 6 months (2021-07-27) | -36.94% |
| 1 year (2021-01-27) | -63.67% |
|---|---|
| 2 years (2020-01-23) | N/A |
| 3 years (2019-01-23) | N/A |
| 5 years (2017-01-23) | N/A |
| Revenue TTM | $14,000 |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -29.85% |
| Return on equity TTM | -57.64% |
| Profit margin | 0% |
| Book value | $3.63 |
| Market capitalisation | $49 million |
TTM: trailing 12 months
We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.
Lyra Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.